Strides Pharma Science share price
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,085.60down ₹7.70 (0.70%)BSE ₹1,087.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,093.30.
28 Oct: open ₹1,093.30, high ₹1,109.90, low ₹1,077.40
52-week range of traded prices to 28 Oct 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹10,006 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 16.31
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.22
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.46%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,96,04549.0% delivered
Results
Consolidated; ₹ crore.Strides Pharma Science quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +7.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,265 Crdown 4.39%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹165 Crup 28.01%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 13.1%
Revenue by quarter
Net profit by quarter, a loss in red
The quarters either side of a change of basis do not compare. From the quarter to Mar 2025, the company's revenue for the year to Mar 2025, ₹4,565 Cr, differs from its quarters added, ₹4,633 Cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,201 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| Net profit | 94 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| Net margin | 7.8% | 7.8% | 7.2% | 9.4% | 10.8% | 17.4% | 9.8% | 13.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4,859 Crup 6.43%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹575 Crdown 84.03%
- Net margin
- 11.8%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 3 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹2,839 Cr, differs from its quarters added, ₹3,251 Cr. From the year to Mar 2019, the company reports a discontinued business. From the year to Mar 2024, the company reports the part of the business demerged on 6 Dec 2024 as discontinued, and figures before the change include it. From the year to Mar 2025, the company's revenue for that year, ₹4,565 Cr, differs from its quarters added, ₹4,633 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,483 | 2,839 | 3,012 | 2,752 | 3,316 | 3,070 | 3,688 | 4,051 | 4,565 | 4,859 |
| Net profit | 446 | 680 | 330 | 31 | 258 | −474 | −212 | −94 | 3,598 | 575 |
| Net margin | 12.8% | 24.0% | – | – | 7.8% | −15.4% | −5.8% | – | – | 11.8% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2019, Mar 2020, Mar 2024 and Mar 2025: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the years to Mar 2018, Mar 2019, Mar 2024 and Mar 2025: days before it are of the company before the change.Strides Pharma Science PE ratio and valuation
Price to earnings
At or below today's level on 38% of 183 trading days over the last year.
LowestHighest
Its median17.10Industry median28.20
Price to book
At or below today's level on 83% of 1,867 trading days since Nov 2018.
LowestHighest
Its median1.96Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 63% of 2,404 trading days over the last 10 years.
LowestHighest
Its median0.41%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | With the demerger reinvestedReturn with the demerger reinvested. The yearly price growth with the price before the demerger multiplied by the demerger's price factor (its opening price on the ex-date over the close before it), plus the average dividend yield: the return of a holder who put the value of the shares of the company that was split off back into this share on the ex-date. | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|---|
| 1 year | +40.7% | – | −84.5% | +807.0% | 0.5% |
| 3 years | +49.0% | +96.1% | – | – | 0.5% |
| 5 years | +2.5% | +20.9% | +15.0% | −11.2% | 0.4% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Return a year is the share as it traded across the demerger; the next column is the same return with the demerger reinvested, empty for a window with no demerger in it. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2021 and Mar 2025.
Mutual fund holdings
15 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 8 of the 12 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 15 funds holding Strides Pharma Science
- AddedAdded. Funds that held more shares than at the end of the month before.
- 6
- CutCut. Funds that held fewer shares than at the end of the month before.
- 6
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 3
| Fund | |||
|---|---|---|---|
 quant Small Cap Fundquant Mutual Fund | 39,29,137 | 1.24% | ₹440.1 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 26,20,885 | 0.82% | ₹293.5 Cr |
| quant Multi Cap Fundquant Mutual Fund | 14,22,000 | 2.12% | ₹159.3 Cr |
 Axis Small Cap FundAxis Mutual Fund | 7,35,028 | 0.27% | ₹82.3 Cr |
| quant Healthcare Fundquant Mutual Fund | 3,42,537 | 9.04% | ₹38.4 Cr |
 Aditya Birla Sun Life Value FundAditya Birla Sun Life Mutual Fund | 3,26,991 | 0.55% | ₹36.6 Cr |
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 1,79,543 | 0.83% | ₹20.1 Cr |
| Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 1,849 | 0.47% | ₹0.21 Cr |
 Groww Nifty Total Market Index FundGroww Mutual Fund | 1,173 | 0.04% | ₹0.13 Cr |
| Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 872 | 0.47% | ₹0.10 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Strides Pharma Science insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 54 pledge filings of unclear kind
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Strides Pharma Science competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Strides Pharma Science in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 CORONA RemediesCORONA | 13,459 | 67.62 | 18.02 | – | – | 26.6% | 30.9% | 0.45% |
 Concord BiotechCONCORDBIO | 13,271 | 46.98 | 6.39 | +4.0% | −12.8% | 14.5% | 15.9% | 0.60% |
 Akums Drugs and PharmaceuticalsAKUMS | 11,375 | 38.99 | 3.43 | +9.2% | −14.6% | 9.2% | 12.0% | 0.42% |
 Viyash ScientificVIYASH | 10,025 | – | 3.44 | +96.5% | – | – | 11.2% | 0.00% |
 Blue Jet HealthcareBLUEJET | 9,802 | 41.73 | – | −27.5% | −34.5% | 18.8% | 18.1% | 0.23% |
 Procter & Gamble HealthPGHL | 8,962 | 25.11 | 17.09 | – | – | 67.2% | 84.2% | 3.80% |
 Symbiotec PharmalabSYMBIOTEC | 8,191 | – | – | – | – | – | – | 0.00% |
 Aarti PharmalabsAARTIPHARM | 7,998 | – | 3.55 | +13.4% | – | – | 11.9% | 0.40% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Strides Pharma Science dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹14.00 a share, year to Mar 2020.
| Ex-date | Type | Per share |
|---|---|---|
| 31 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹5.00 |
| 22 Jul 2025 | Final | ₹4.00 |
| 9 Sep 2024 | Final | ₹2.50 |
| 4 Aug 2023 | Final | ₹1.50 |
| 5 Aug 2021 | Final | ₹2.50 |
| 24 Jul 2020 | Final | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Strides Pharma Science announcements
Oct 2026
23 Oct · Analysts
23 Oct · Board meeting
Sep 2026
23 Sep · General Updates
11 Sep · General Updates
Aug 2026
Strides Pharma Science share price by year
Each calendar year to 2025.Strides Pharma Science share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 900.35 | +36.5% | 984.80 | 570.60 |
| 2024Demerger | 659.40 | +1.6% | 1,643.30 | 652.95 |
| 2023 | 649.25 | +85.6% | 652.70 | 271.70 |
| 2022 | 349.85 | −21.7% | 456.50 | 266.40 |
| 2021 | 447.05 | −49.1% | 973.75 | 410.55 |
| 2020 | 878.20 | +142.6% | 910.10 | 274.05 |
| 2019 | 361.95 | −21.5% | 548.30 | 304.15 |
| 2018 | 461.00 | −44.0% | 828.10 | 341.00 |
| 2017 | 822.95 | −22.5% | 1,206.60 | 762.10 |
| 2016 | 1,062.20 | −17.6% | 1,305.30 | 874.45 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. With the demerger of 6 Dec 2024 reinvested, the change in 2024 is +132.0%.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,025.50 | 1,116.40 | 1,025.50 | 1,093.30 | 1,095.20 | 7,87,306 | 47.7% |
| 26 Oct 2026 | 1,006.50 | 1,053.90 | 1,001.00 | 1,033.10 | 1,034.50 | 2,81,520 | 51.6% |
| 23 Oct 2026 | 1,000.00 | 1,023.60 | 980.40 | 1,014.80 | 1,002.77 | 3,12,385 | 41.2% |
| 22 Oct 2026 | 1,015.00 | 1,029.80 | 994.20 | 998.40 | 1,011.01 | 2,23,577 | 55.6% |
| 21 Oct 2026 | 1,021.00 | 1,031.00 | 1,002.70 | 1,025.30 | 1,018.70 | 1,44,622 | 49.4% |
| 19 Oct 2026 | 1,050.00 | 1,050.00 | 1,015.90 | 1,029.30 | 1,035.35 | 2,24,715 | 52.6% |
| 16 Oct 2026 | 1,060.00 | 1,066.00 | 1,040.00 | 1,045.20 | 1,051.25 | 2,07,930 | 50.3% |
| 15 Oct 2026 | 1,080.10 | 1,089.20 | 1,051.30 | 1,059.90 | 1,074.70 | 2,53,392 | 50.6% |
| 14 Oct 2026 | 1,087.00 | 1,094.00 | 1,071.70 | 1,084.80 | 1,082.98 | 1,84,350 | 46.3% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Demerger history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 6 Dec 2024 | Demerger | 0.4377 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
| 18 May 2018 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company's board met on results that day or since the trading day before. Not adjusted for. |
| 19 Dec 2013 | Price move | – | A corporate action went ex within three days of this move (Special Dividend - Rs 500/- Per Share, ex-date 19 Dec 2013), and its terms do not account for the move. Earlier prices are not shown. |
| 22 Jan 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. The Nifty 500 moved 5% or more the same way over the same sessions. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- STAR
- BSE code
- 532531
- ISIN
- INE939A01011
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.strides.com
- CIN
- L24230MH1990PLC057062
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1990
- Registered office
- Cyberone, Unit No. 902, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai 400703, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments